What oral medications are recommended for treating amyotrophic lateral sclerosis (ALS)?

Oral Medications for Amyotrophic Lateral Sclerosis (ALS)

Two oral medications are FDA-approved for treating ALS: riluzole and oral edaravone, both of which modestly slow disease progression by 2-4 months and should be initiated at diagnosis in eligible patients 1.

First-Line Oral Disease-Modifying Therapy

Riluzole

• Start riluzole immediately upon ALS diagnosis as the gold standard oral therapy 2
• Extends survival by 6-19 months in real-world settings, substantially more than the 2-4 months shown in clinical trials 1, 2
• Dosing: Standard tablet formulation initially; switch to oral suspension or oral film if dysphagia develops 2
• Key advantage: Riluzole oral suspension can be administered via PEG tube when severe dysphagia occurs 2
• Monitoring: Check liver enzymes regularly; 10% of patients develop transient elevation 2
• Common side effects: Non-severe gastrointestinal complications, transient oral hypoesthesia with oral film 2

Oral Edaravone

• FDA-approved in 2022 as an oral suspension formulation (105 mg) 3, 4
• Bioavailability of 57% compared to IV formulation 3
• Administration: Take on empty stomach in the morning with water; no food or beverages for 1 hour 3, 5
• Can be given through feeding tube (flush before and after) 5
• Mechanism: Neuroprotective through antioxidant properties and free radical elimination 3
• Common adverse events: Falls, muscular weakness, constipation 3
• Serious adverse events: Disease worsening, dysphagia, dyspnea, respiratory failure 3

Combination Therapy Considerations

Up to 3-4 anti-ALS agents can now be used simultaneously in clinical practice 6. The long-term safety and potential synergistic effects of combination therapy remain under investigation through real-world registries 6.

Gene-Specific Therapy

For patients with SOD1 gene variants (20% of familial ALS cases):

• Tofersen is available as intrathecal gene therapy (not oral) 1, 6
• Genetic testing should be performed in all ALS patients to identify candidates for gene-targeted therapies 6

High-Dose Mecobalamin (Japan)

High-dose intramuscular mecobalamin (not oral) reduces functional decline when initiated early in disease course 6. This is approved in Japan but not widely available elsewhere.

Critical Pitfalls to Avoid

1. Do not delay riluzole initiation - Start at diagnosis, not when symptoms worsen
2. Do not crush riluzole tablets for dysphagia - This causes drug loss and aspiration risk; switch to oral suspension or film instead 2
3. Do not administer oral edaravone with food - Requires empty stomach for proper absorption 3
4. Do not overlook genetic testing - SOD1 variants qualify patients for tofersen therapy 6

Treatment Algorithm

1. At diagnosis: Start riluzole tablets immediately
2. When dysphagia develops: Switch to riluzole oral suspension or oral film
3. Consider adding oral edaravone at diagnosis or early in disease course
4. If SOD1-positive: Add tofersen (intrathecal, not oral)
5. Monitor: Liver enzymes for riluzole; functional decline for all therapies

The evidence emphasizes that no curative therapies exist 1, and these oral medications provide modest disease modification while specialized multidisciplinary care improves survival by 4-7 months and quality of life 1.